A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin α: A prospective randomized controlled trial of the ELYPSE study group

Annals of Oncology

Volumn 20, Issue 6, 2009, Pages 1105-1112

  Ray Coquard, I ^a,i   Dussart, S ^a   Goillot, C ^b   Mayeur, D ^c   Debourdeau, P ^d   Ghesquieres, H ^a   Bachelot, T ^a   Le Cesne, A ^f   Anglaret, B ^g   Agostini, C ^h   Guastalla, J P ^a   Lancry, L ^a   Biron, P ^a   Desseigne, F ^a   Blay, J Y ^a,e  

^a UNIVERSITÉ DE LYON   (France)

^b Oncology Hematology Department   (France)

^c Foch Hospital   (France)

^d HIA Desgenettes   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f Oncology Department   (France)

^g Chambery Hospital   (France)

^h EDOUARD HERRIOT HOSPITAL   (France)

ⁱ CENTRE LÉON BÉRARD   (France)

Author keywords

Cancer patients; Chemotherapy; Epoetin; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL MODEL; BLOOD ANALYSIS; BLOOD TRANSFUSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; DRUG SAFETY; ERYTHROPOIESIS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; IRON DEFICIENCY; LUNG CARCINOMA; LYMPHOCYTE COUNT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SARCOMA; SOLID TUMOR; THROMBOSIS;

EID: 66149103228     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn750     Document Type: Article

References (35)

1. Ludwig H, Fritz E, Leitgeb C et al. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol 1993; 4: 161-167.
2. Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997; 15: 1218-1234.
3. Minton O, Richardson A, Sharpe M et al. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst 2008; 100: 1155-1166.
4. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-2874.
5. Case DC Jr, Bukowski RM, Carey RW et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993; 85: 801-806.
6. Demetri GD, Kris M, Wade J et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998; 16: 3412-3425.
7. Smith DH, Adams JR, Johnston SR et al. A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Ann Oncol 2002; 13: 1590-1597.
8. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4: 459-460.
9. Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007; 25: 1027-1032.
10. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255-1260.
11. Henke M, Mattern D, Pepe M et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006; 24: 4708-4713.
12. Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299: 914-924.
13. Bohlius J, Wilson J, Seidenfeld J et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006; 3: CD003407.
14. Rizzo JD, Somerfield MR, Hagerty KL et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008; 26: 132-149.
15. Somerfield MR, Einhaus K, Hagerty KL et al. American Society of Clinical Oncology clinical practice guidelines: Opportunities and challenges. J Clin Oncol 2008; 26: 4022-4026.
16. Ray-Coquard I, Le Cesne A, Rubio MT et al. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol 1999; 17: 2840-2846.
17. Marec-Berard P, Blay JY, Schell M et al. Risk model predictive of severe anemia requiring RBC transfusion after chemotherapy in pediatric solid tumor patients. J Clin Oncol 2003; 21: 4235-4238.
18. Aapro M, Scherhag A, Burger HU. Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: An updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br J Cancer 2008; 99: 14-22.
19. Demetri GD. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer 2001; 84: 31-37.
20. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 1994; 12: 2471-2508.
21. Koeller JM. Clinical guidelines for the treatment of cancer-related anemia. Pharmacotherapy 1998; 18: 156-169.
22. Biron P, Fuhrmann C, Escande MC et al. [Standards, options, and recommendations for the management of brief neutropenias. Federation Nationale des Centres de Lutte Contre le Cancer]. Bull Cancer 1998; 85: 695-711.
23. Kaplan ECMP. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 437-481.
24. Ray-Coquard I, Ghesquiere H, Bachelot T et al. Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer 2001; 85: 816-822.
25. Khuri FR. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 2007; 356: 2445-2448.
26. Ray-Coquard I, Kassab-Chahmi D, Casadevall N et al. [Clinical practice guidelines for the use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, darbepoetin) in anaemic patients with cancer: 2007 update (summary report)]. Bull Cancer 2008; 95: 433-441.
27. Glaser CM, Millesi W, Kornek GV et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001; 50: 705-715.
28. Osterborg A, Brandberg Y, Hedenus M. Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: Long-term follow up of a large randomized study. Br J Haematol 2005; 129: 206-209.
29. Bohlius J, Langensiepen S, Schwarzer G et al. Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev 2004; 3: CD003407.
30. Ray-Coquard I, Blay JY, Sebban C et al. Lymphopenia ≤ 700/L and performance status > 1 as prognostic factors of early death after conventional cytotoxic chemotherapy. 35th annual meeting of the American Society of Clinical Oncology. Atlanta, GA 1999; 576 (Abstr. 2225).
31. Ray-Coquard I, Borg C, Bachelot T et al. [Prognostic factors for febrile neutropenia]. Bull Cancer 2006; 93: 501-506.
32. Borg C, Ray-Coquard I, Philip I et al. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer 2004; 101: 2675-2680.
33. Blay JY, Le Cesne A, Mermet C et al. A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood 1998; 92: 405-410.
34. Blay JY, Ray-Coquard I, Mermet C et al. a multicentric prospective study of prognostic factors for febrile neutropenia after chemotherapy in general and cancer hospitals. J Clin. Oncol 1997; 16: 56a (Abstr).
35. Claude L, Perol D, Ray-Coquard I et al. Lymphopenia: A new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma. Radiother Oncol 2005; 76: 334-339.